MENA Congress For Rare Diseases 2025 Commences In Abu Dhabi With Global Experts

The MENA Congress for Rare Diseases 2025 commenced today in Abu Dhabi, marking the region's largest event focused on rare diseases. In collaboration with Burjeel Medical City, this four-day gathering features 160 speakers, including 55 international experts from 24 countries. The congress aims to discuss recent advancements in diagnosing, treating, and researching rare diseases.

With over 1,500 participants, including 30% from outside the UAE representing more than 50 countries, the congress serves as a crucial platform for global collaboration and knowledge exchange. Prof. Ayman El-Hattab, Congress President and Director of the Genetics and Rare Disease Centre at Burjeel Medical City, emphasised the event's importance: "This congress is a unique platform that brings all stakeholders involved in rare diseases to one place to obtain the most updated knowledge, exchange experiences, advance research, and explore new collaborations. Our aim is to ultimately improve the care and quality of life for individuals living with rare diseases in the region and beyond."

Prof. Khaled Musallam, Head of the Scientific Committee and Group Chief Research Officer at Burjeel Holdings, highlighted the scientific depth of the congress. He stated that the MENA region faces a significant burden of rare diseases. The congress demonstrates a shared commitment to addressing gaps in care, diagnostics, and treatment through science and innovation. "Through science, innovation, and collaboration, we are shaping a better future for patients affected by rare diseases," he noted.

A notable feature of this year's congress is its focus on Burjeel Medical City's new Genetics and Rare Disease Centre. This centre offers comprehensive care based on evidence for individuals with rare genetic conditions.

The opening ceremony included presenting the Award for Outstanding Achievements in Rare Diseases to several distinguished individuals. Honourees included Alexandra Heumber Perry, CEO of Rare Diseases International; Svein Olaf Olsen from Anzyz Technologies AS; Dr. Khawla Alshehhi from The British University in Dubai; Prof. Brahim Tabarki Melaiki from Prince Sultan Military Medical City in Saudi Arabia; Dr. Mohamed Alameri from DOH – Abi Dhabi; and Dr. David Kasper from ARCHIMEDlife GmbH in Austria.

This event underscores a collective effort to enhance understanding and treatment of rare diseases globally. By bringing together experts from various fields, it fosters an environment conducive to advancing research and improving patient outcomes.

With inputs from WAM